Literature DB >> 8717612

Clozapine withdrawal effects and receptor profiles of typical and atypical neuroleptics.

C Verghese1, J DeLeon, C Nair, G M Simpson.   

Abstract

Withdrawal effects of neuroleptics have not received much attention. Clozapine withdrawal phenomena have been attributed to psychosis arising from D2 supersensitivity, which is unlikely since it has minimal action on D2 receptors. The time course and clinical features of this phenomenon suggest that cholinergic overdrive and gamma-aminobutyric acid (GABA) supersensitivity occurs after withdrawal, since it is strongly anticholinergic and has a GABAergic action. Recently, a number of patients showed marked decompensation when they were switched from clozapine to risperidone, especially when they were rapidly tapered off clozapine. This was probably more due to withdrawal effects than the primary psychosis or a lack of efficacy of risperidone. A slow withdrawal schedule would facilitate homeostatic mechanisms; anticholinergics would be useful in clozapine withdrawal. This area has not received any attention from researchers, nor are there any guidelines for clinicians. This will be particularly important with the widespread use of atypical agents in the future.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8717612     DOI: 10.1016/0006-3223(95)00215-4

Source DB:  PubMed          Journal:  Biol Psychiatry        ISSN: 0006-3223            Impact factor:   13.382


  11 in total

Review 1.  Switching between second-generation antipsychotics: why and how?

Authors:  Monika Edlinger; Susanne Baumgartner; Nadja Eltanaihi-Furtmüller; Martina Hummer; W Wolfgang Fleischhacker
Journal:  CNS Drugs       Date:  2005       Impact factor: 5.749

Review 2.  The role of long-acting injectable antipsychotics in schizophrenia: a critical appraisal.

Authors:  Sofia Brissos; Miguel Ruiz Veguilla; David Taylor; Vicent Balanzá-Martinez
Journal:  Ther Adv Psychopharmacol       Date:  2014-10

3.  The effects of neuroleptics on the GABA-induced Cl- current in rat dorsal root ganglion neurons: differences between some neuroleptics.

Authors:  Kenjiro Yokota; Hideharu Tatebayashi; Tadashi Matsuo; Takashi Shoge; Haruhiko Motomura; Toshiyuki Matsuno; Akira Fukuda; Nobutada Tashiro
Journal:  Br J Pharmacol       Date:  2002-03       Impact factor: 8.739

Review 4.  The relevance of neuroactive steroids in schizophrenia, depression, and anxiety disorders.

Authors:  Erin M MacKenzie; John Odontiadis; Jean-Michel Le Mellédo; Trevor I Prior; Glen B I Baker
Journal:  Cell Mol Neurobiol       Date:  2007-08       Impact factor: 5.046

5.  Mechanisms of action of antipsychotic drugs of different classes, refractoriness to therapeutic effects of classical neuroleptics, and individual variation in sensitivity to their actions: Part II.

Authors:  R Miller
Journal:  Curr Neuropharmacol       Date:  2009-12       Impact factor: 7.363

6.  Catatonia Secondary to Sudden Clozapine Withdrawal: A Case with Three Repeated Episodes and a Literature Review.

Authors:  John Bilbily; Betsy McCollum; Jose de Leon
Journal:  Case Rep Psychiatry       Date:  2017-03-15

Review 7.  Review of withdrawal catatonia: what does this reveal about clozapine?

Authors:  Matthew Lander; Tarun Bastiampillai; Jitender Sareen
Journal:  Transl Psychiatry       Date:  2018-07-31       Impact factor: 6.222

8.  Closure beyond clozapine: successfully averting rebound symptoms in a patient with schizoaffective disorder and agranulocytosis.

Authors:  Alastair Green; Thomas Stephenson; Eromona Whiskey; Sukhi S Shergill
Journal:  BJPsych Open       Date:  2019-05-22

9.  A case report of cholinergic rebound syndrome following abrupt low-dose clozapine discontinuation in a patient with type I bipolar affective disorder.

Authors:  Andrea Galova; Patricia Berney; Jules Desmeules; Ioannis Sergentanis; Marie Besson
Journal:  BMC Psychiatry       Date:  2019-02-19       Impact factor: 3.630

10.  Neuroleptic malignant syndrome and subsequent clozapine-withdrawal effects in a patient with refractory schizophrenia.

Authors:  Minfeng Cheng; Huaying Gu; Liangrong Zheng; Houliang Wang; Zhiyong Zhong; Shenglin Wen
Journal:  Neuropsychiatr Dis Treat       Date:  2016-03-29       Impact factor: 2.570

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.